JP2023546671A5 - - Google Patents
Info
- Publication number
- JP2023546671A5 JP2023546671A5 JP2023524521A JP2023524521A JP2023546671A5 JP 2023546671 A5 JP2023546671 A5 JP 2023546671A5 JP 2023524521 A JP2023524521 A JP 2023524521A JP 2023524521 A JP2023524521 A JP 2023524521A JP 2023546671 A5 JP2023546671 A5 JP 2023546671A5
- Authority
- JP
- Japan
- Prior art keywords
- iscb
- activity
- protein
- composition according
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063105191P | 2020-10-23 | 2020-10-23 | |
| US202063105177P | 2020-10-23 | 2020-10-23 | |
| US63/105,191 | 2020-10-23 | ||
| US63/105,177 | 2020-10-23 | ||
| US202163156857P | 2021-03-04 | 2021-03-04 | |
| US63/156,857 | 2021-03-04 | ||
| US202163195659P | 2021-06-01 | 2021-06-01 | |
| US63/195,659 | 2021-06-01 | ||
| US202163235583P | 2021-08-20 | 2021-08-20 | |
| US63/235,583 | 2021-08-20 | ||
| PCT/US2021/056361 WO2022087494A1 (en) | 2020-10-23 | 2021-10-22 | Reprogrammable iscb nucleases and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023546671A JP2023546671A (ja) | 2023-11-07 |
| JP2023546671A5 true JP2023546671A5 (enExample) | 2024-10-25 |
Family
ID=81289497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023524521A Pending JP2023546671A (ja) | 2020-10-23 | 2021-10-22 | 再プログラム可能なｉｓｃｂヌクレアーゼ及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230392131A1 (enExample) |
| EP (1) | EP4203993A4 (enExample) |
| JP (1) | JP2023546671A (enExample) |
| KR (1) | KR20230111189A (enExample) |
| AU (1) | AU2021364399A1 (enExample) |
| CA (1) | CA3193961A1 (enExample) |
| IL (1) | IL302101A (enExample) |
| WO (1) | WO2022087494A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10913941B2 (en) | 2019-02-14 | 2021-02-09 | Metagenomi Ip Technologies, Llc | Enzymes with RuvC domains |
| US20230040216A1 (en) * | 2019-11-19 | 2023-02-09 | The Broad Institute, Inc. | Retrotransposons and use thereof |
| CA3177051A1 (en) | 2020-03-31 | 2021-10-07 | Metagenomi, Inc. | Class ii, type ii crispr systems |
| EP4225928A4 (en) * | 2020-10-09 | 2025-04-30 | The Broad Institute, Inc. | GENETIC MODIFICATION USING A HELITRON |
| CN119452085A (zh) | 2021-08-27 | 2025-02-14 | 宏基因组学公司 | 具有ruvc结构域的酶 |
| WO2023097228A1 (en) * | 2021-11-23 | 2023-06-01 | The Broad Institute, Inc. | Reprogrammable iscb nucleases and uses thereof |
| KR20240110603A (ko) | 2021-11-24 | 2024-07-15 | 메타지노미, 인크. | 엔도뉴클레아제 시스템 |
| US20250283116A1 (en) * | 2022-05-06 | 2025-09-11 | Cornell University | Use of iscb in genome editing |
| WO2023230483A2 (en) * | 2022-05-23 | 2023-11-30 | The Broad Institute, Inc. | Engineered chimeric iscb polypeptides and uses thereof |
| JP2025525583A (ja) | 2022-07-19 | 2025-08-05 | ランパート バイオサイエンス インコーポレイテッド | 非免疫原性環状非ウイルス性ｄｎａベクター |
| WO2024038168A1 (en) * | 2022-08-19 | 2024-02-22 | UCB Biopharma SRL | Novel rna-guided nucleases and nucleic acid targeting systems comprising such |
| WO2024083135A1 (en) * | 2022-10-17 | 2024-04-25 | Huidagene Therapeutics (Singapore) Pte. Ltd. | Iscb polypeptides and uses thereof |
| WO2024094084A1 (en) * | 2022-11-01 | 2024-05-10 | Huidagene Therapeutics Co., Ltd. | Iscb polypeptides and uses thereof |
| CN118620868A (zh) * | 2023-03-07 | 2024-09-10 | 上海科技大学 | IscBn-ωRNA编辑系统及其应用 |
| WO2024192141A1 (en) | 2023-03-13 | 2024-09-19 | Dana-Farber Cancer Institute, Inc. | Treatment of cancers having a drug-resistant mesenchymal cell state |
| WO2024192291A1 (en) | 2023-03-15 | 2024-09-19 | Renagade Therapeutics Management Inc. | Delivery of gene editing systems and methods of use thereof |
| WO2024197185A1 (en) | 2023-03-21 | 2024-09-26 | The Broad Institute, Inc. | Methods and compositions for dissecting organelle physiology |
| WO2024206825A2 (en) * | 2023-03-31 | 2024-10-03 | Aera Therapeutics, Inc. | Modified iscb nucleases, modified guide rnas, and uses thereof |
| WO2024220715A2 (en) * | 2023-04-19 | 2024-10-24 | Mammoth Biosciences, Inc. | Effector proteins and uses thereof |
| WO2024226838A2 (en) | 2023-04-25 | 2024-10-31 | The Brigham And Women's Hospital, Inc. | Treatment of autoimmune diseases having a pathogenic t cell state |
| WO2025007044A1 (en) * | 2023-06-28 | 2025-01-02 | The University Of Chicago | Methods and compositions comprising iscb variants |
| WO2025049788A1 (en) | 2023-08-29 | 2025-03-06 | The Broad Institute, Inc. | Optical genetic screens of intracellular and intercellular transcriptional circuits with perturb-fish |
| EP4771154A2 (en) | 2023-09-01 | 2026-07-08 | Renagade Therapeutics Management Inc. | Gene editing systems, compositions, and methods for treatment of vexas syndrome |
| WO2025096916A1 (en) | 2023-11-03 | 2025-05-08 | The Broad Institute, Inc. | Multi-site editing in living cells |
| WO2025100980A1 (ko) * | 2023-11-08 | 2025-05-15 | 한국과학기술원 | Ube3a를 표적으로 하여 발현증강을 유도하는 안티센스 올리고뉴클레오티드 및 이의 용도 |
| WO2025101679A1 (en) * | 2023-11-10 | 2025-05-15 | Mammoth Biosciences, Inc. | Effector proteins and uses thereof |
| WO2025117544A1 (en) | 2023-11-29 | 2025-06-05 | The Broad Institute, Inc. | Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof |
| WO2025129158A1 (en) | 2023-12-15 | 2025-06-19 | The Broad Institute, Inc. | Engineered arc delivery vesicles and uses thereof |
| WO2025149083A1 (en) * | 2024-01-11 | 2025-07-17 | Huidagene Therapeutics Co., Ltd. | Iscb polypeptides and uses thereof |
| WO2025155923A1 (en) | 2024-01-17 | 2025-07-24 | The Broad Institute, Inc. | Aav capsid modifications that enable improved cns-wide gene delivery through interactions with the transferrin receptor |
| WO2025160155A1 (en) | 2024-01-22 | 2025-07-31 | The Broad Institute, Inc. | Epigenetic targeting of prion diseases |
| WO2025174765A1 (en) | 2024-02-12 | 2025-08-21 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025217174A1 (en) | 2024-04-08 | 2025-10-16 | The Broad Institute, Inc. | Aav capsid modifications that enable improved cns-wide gene delivery through interactions with carbonic anhydrase iv |
| WO2025217163A2 (en) | 2024-04-08 | 2025-10-16 | The Broad Institute, Inc. | Novel aav capsids binding to human cd59 |
| WO2026107393A2 (en) | 2024-11-14 | 2026-05-21 | The Broad Institute, Inc. | Aav capsid modifications that reduce immunogenicity |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018035250A1 (en) * | 2016-08-17 | 2018-02-22 | The Broad Institute, Inc. | Methods for identifying class 2 crispr-cas systems |
| US12534714B2 (en) * | 2019-03-18 | 2026-01-27 | The Broad Institute, Inc. | Type VII CRISPR proteins and systems |
| WO2020191241A1 (en) * | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
-
2021
- 2021-10-22 EP EP21884039.5A patent/EP4203993A4/en active Pending
- 2021-10-22 AU AU2021364399A patent/AU2021364399A1/en active Pending
- 2021-10-22 KR KR1020237015731A patent/KR20230111189A/ko active Pending
- 2021-10-22 IL IL302101A patent/IL302101A/en unknown
- 2021-10-22 US US18/032,868 patent/US20230392131A1/en active Pending
- 2021-10-22 WO PCT/US2021/056361 patent/WO2022087494A1/en not_active Ceased
- 2021-10-22 JP JP2023524521A patent/JP2023546671A/ja active Pending
- 2021-10-22 CA CA3193961A patent/CA3193961A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL302101A (en) | Reprogrammable iscb nucleases and uses thereof | |
| JP6737974B1 (ja) | ヌクレアーゼ媒介ｄｎａアセンブリ | |
| JP7153992B2 (ja) | Ｒｎａ誘導性遺伝子制御および編集のための直交性ｃａｓ９タンパク質 | |
| CN102124112B (zh) | 基于同源重组dna的克隆方法及组合物 | |
| CN113373130A (zh) | Cas12蛋白、含有Cas12蛋白的基因编辑系统及应用 | |
| EP3004349B1 (en) | A method for producing precise dna cleavage using cas9 nickase activity | |
| JP7292258B2 (ja) | 縦列反復配列を有するドナーｄｎａ修復鋳型を使用する部位特異的なｄｎａ改変 | |
| CN114269913B (zh) | 胞嘧啶碱基编辑组合物及其用途 | |
| JP2023501002A5 (enExample) | ||
| WO2017215648A1 (zh) | 基因敲除方法 | |
| US20200232005A1 (en) | Methods of Producing and Using Single-Stranded Deoxyribonucleic Acids and Compositions for Use in Practicing the Same | |
| JP2020510443A (ja) | 細胞ゲノムにおける、相同組換え修復（ｈｄｒ）の効率を上昇させるための方法 | |
| JP7762651B2 (ja) | 修飾二重鎖ドナー鋳型 | |
| JP7416745B2 (ja) | 改変細胞、調製方法、及び構築物 | |
| CN119162157B (zh) | 用于碱基编辑的脱氨酶及其变体 | |
| WO2025049563A1 (en) | A programmable gene correction technology using cas-polymerase constructs | |
| Ishino | Studies on DNA-related enzymes to elucidate molecular mechanisms underlying genetic information processing and their application in genetic engineering | |
| JP4854160B2 (ja) | Ｄｎａの連結方法 | |
| CN118715317A (zh) | Dna聚合酶介导的基因组编辑 | |
| Palanivelu | Analyses of Homing Endonucleases and Mechanism of Action of CRISPR-Cas9 HNH Endonucleases | |
| US20060147961A1 (en) | Methods for ligation independent cloning of DNA | |
| JP3882035B1 (ja) | Ｄｎａシャフリング | |
| KR20050009118A (ko) | 티벡터와 발현벡터로의 기능을 동시에 가지는 플라스미드및 이를 이용한 목적유전자의 발현 | |
| CN120518784A (zh) | 一种核苷酸序列编辑方法及具有编辑作用的融合蛋白 | |
| Lyozin et al. | DNA gap repair-mediated site-directed mutagenesis is different from Mandecki and recombineering approaches |